DRUG INFORMATION RESOURCES - INTERNATIONAL
Methamphetamine – the Respiratory System & Covid-19: Bad Combination
The Substance Abuse and Mental Health Services Administration (SAMHSA) is the agency within the U.S. Department of Health and Human Services that leads public health efforts to advance the behavioral health of the nation. SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America's communities.
- Details
- Hits: 518
(Not ‘Recreational’ Drugs – But Recreational use of toxic substances)
Recreational drug use poses significant health risks, particularly concerning cardiovascular health. Recent findings presented at the European Society of Cardiology (ESC) Congress 2024 reveal the alarming impact of recreational drugs on the likelihood of repeat serious cardiovascular events. The study underscores the urgent need for healthcare systems to address drug use effectively within cardiac care settings.
Study Insights from the ESC Congress 2024: The research, conducted as part of the Addiction in Intensive Cardiac Care Units (ADDICT-ICCU) study, investigated the prognostic impact of recreational drug use on patients admitted to intensive cardiac care units (ICCU) across 39 centres in France. Over two weeks in April 2021, systematic urinary testing revealed that 11% of patients had recently used recreational drugs, including cannabis, heroin, opioids, cocaine, amphetamines, and MDMA.
Key Findings: Patients with a recent history of recreational drug use faced a tripled risk of experiencing a repeat serious cardiovascular event, such as cardiovascular death, non-fatal heart attack, or stroke, within one year of their initial admission. After adjusting for various factors, including age, sex, and existing health conditions, recreational drug use remained an independent predictor of adverse cardiovascular outcomes.
The study found that among 1,392 patients screened, 64 (4.6%) experienced cardiovascular deaths, with a higher incidence among drug users (5.7%) compared to non-users (4.5%). Non-fatal heart attacks occurred in 24 patients (1.7%), with drug users showing a higher incidence (5.1%) compared to non-users (1.3%). Strokes were similarly more common among drug users (1.9%) than non-users (0.6%).
Specific Drug Risks: The type of drug used also influenced cardiovascular risk. MDMA users exhibited a 4.1 times increased risk, those using heroin and other opioids faced a 3.6 times higher risk, and cannabis users had a 1.8 times increased risk of serious cardiovascular events. These statistics highlight the varying impacts of different substances on heart health.
Healthcare Implications: Given the significant risks associated with recreational drug use, the study’s authors advocate for routine screening of ICCU patients for recent drug use. This proactive approach could enhance risk stratification and enable personalised care strategies, including facilitating drug withdrawal programs. Despite the high rate of underreporting drug use, systematic screening is not yet recommended by current guidelines but could provide critical insights into patient care.
Source: ESC
- Details
- Hits: 486
While psychedelic drugs like psilocybin have been touted for their potential therapeutic benefits, it is crucial to examine the darker aspects of these substances. Recent research led by Dr. Joshua Siegel at Washington University in St. Louis highlights the profound risks associated with psilocybin, particularly its ability to disrupt critical brain networks and cause potential long-term psychological harm.
Long-Term Implications: While some brain functions return to normal shortly after psilocybin use, the study noted that certain changes in functional connectivity, particularly between the DMN and the hippocampus, can persist for weeks. These lasting alterations could have unknown long-term effects on mental health, hinting at the possibility of enduring cognitive or emotional disturbances.
Despite the growing interest in the therapeutic potential of psilocybin, the risks associated with its use cannot be overlooked
- Details
- Hits: 650
September, 2024 By WRD News Team
A recent surge of illnesses linked to mushroom edibles has raised significant concerns about the safety and regulation of these products. This issue centres around Amanita muscaria-infused gummies, known for their psychoactive effects, and other synthetic compounds found in these edibles. As more than 140 documented cases of sickness, including two suspected deaths, have been reported, scientists, regulators, and consumers are grappling with the implications of these findings.
The Role of Amanita Muscaria: Amanita muscaria, the red-capped mushroom often depicted in folklore and popular culture, is at the heart of the current health scare. While not federally controlled, it is known for its psychoactive properties, primarily due to compounds like muscimol and ibotenic acid. Muscimol, a compound with sedative effects, and ibotenic acid, a neurotoxin, are both capable of inducing hallucinations and delirium. However, the Amanita species is different from psilocybin-containing mushrooms, which are more commonly associated with psychedelic experiences.
The wave of illnesses has been linked to products marketed under the brand Diamond Shroomz, which were found to contain muscimol in only a fraction of the tested samples. Despite the recall of these products, poison centres continue to receive reports of adverse effects, highlighting the ongoing concern.
Symptoms and Health Risks: The symptoms associated with these mushroom edibles are severe and varied, including nausea, vomiting, seizures, loss of consciousness, and agitation. The inability to pinpoint the exact cause of these symptoms complicates efforts to address the issue. Toxicologists like Dr. Michael Moss have noted the unusual severity of these reactions, which are not typical of mushroom intoxication.
Challenges in Testing: Analysing the contents of these edibles presents a significant challenge. The complexity of identifying compounds like muscimol and ibotenic acid, especially in edible forms like chocolate or gummy candies, makes testing difficult. Moreover, preliminary investigations have uncovered the presence of synthetic psilocybin analogs and other substances like pregabalin and kava, further complicating the safety profile of these products.
Tryptomics, a company specialising in testing psychoactive substances, has identified various unlisted ingredients in over 100 products, underscoring the inconsistency and potential for contamination in the market.
Regulatory Concerns: The proliferation of these unregulated psychoactive products mirrors past issues with synthetic cannabis, raising fears of a regulatory backlash. The lack of oversight allows for the sale of these potentially dangerous edibles, with manufacturers exploiting legal loopholes. Experts like Roger Brown, CEO of ACS Laboratory, acknowledge the gaps in regulation and the challenges of enforcing existing laws.
Industry insiders and health experts express concern over the potential impact on consumers and the need for better regulatory frameworks to ensure safety and transparency in the market.
Potential Solutions and Future Directions: Addressing the risks associated with mushroom edibles requires a multi-faceted approach, including improved testing methods, clearer regulatory guidelines, and consumer education. The ongoing federal investigation aims to determine the root cause of the illnesses and develop strategies to prevent future occurrences.
Consumers are advised to exercise caution, verify product safety through lab analysis, and remain informed about the potential health risks. As interest in microdosing and psychedelic substances grows, ensuring the safety and regulation of these products will be crucial to prevent further public health issues.
Source WRD NEWS
- Details
- Hits: 509
#psychedelics #ScienceMatters
In recent years, psychedelic drugs like psilocybin, LSD, and MDMA have experienced a surge of interest from researchers, pharmaceutical companies, and the media. Touted as potential breakthrough treatments for conditions ranging from depression to addiction, psychedelics have captured the public imagination and garnered significant investment. However, a closer examination of the scientific evidence reveals concerning flaws in much of the existing research, leading to growing scepticism about the therapeutic potential of these substances. (Source: August 2024 WRD News)
- Details
- Hits: 581
The Australian Government wants to protect young people from the harms of vaping and nicotine dependence. From 1 July 2024, nicotine vapes in Australia are regulated as therapeutic goods. This means they are only available at pharmacies to help people quit smoking or manage nicotine dependence. It is illegal for any other business, such as tobacconists, vape shops and convenience stores, to sell any type of vape or vape product.
Until 30 September 2024, everyone needs a prescription from a doctor or nurse practitioner to purchase therapeutic vapes from a pharmacy.
From 1 October 2024, people 18 years or over will be able to purchase nicotine vapes directly from a pharmacy without a prescription.
People under 18 will still need a prescription to access vapes, where state and territory laws allow it, to ensure they get appropriate medical advice and supervision.
The concentration of nicotine in vapes sold in pharmacies without a prescription will be limited to 20mg/ml; people who need vapes with a higher concentration of nicotine will still require a prescription.
Additional changes will limit the flavours available to mint, menthol and tobacco, and require plain pharmaceutical packaging for all vape products.
- Pill Testing: A comprehensive series on Pill Checking/Testing – Get the facts, not the spin. A must read for all Australians, from Politician to Parent to Punter.
- World Drug Report: 2024
- Pill 'CHECKING' sold again on the cynically misused mantra of 'saving lives'.
- New Vaping Regulations – Doing it Correctly – Not Punishing Product